Literature DB >> 14574331

Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma.

B Arnulf1, M Thorel, Y Poirot, R Tamouza, E Boulanger, A Jaccard, E Oksenhendler, O Hermine, C Pique.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy (HAM). In asymptomatic carriers and HAM patients, HTLV-1 infection leads to a vigorous cytotoxic T-cell (CTL) response mainly directed to the regulatory Tax protein. In contrast, initial studies showed that anti-HTLV-1 CTL activities were not reproductively detected in ATLL patients, neither ex vivo, nor after in vitro restimulation. To better understand this discrepancy, we explored the anti-HTLV-1 CD8+ T-cell response of eight ATLL patients by using in vitro restimulated or freshly isolated CD8+ T cells. In all the ATLL patients, we found that mitogenic activation allowed the induction of CD8+ T cells able to lyse autologous HTLV-1-infected cells and/or to produce IFNgamma in response to Tax peptides. In contrast, only a minority of the patients possessed CD8+ cells able to respond ex vivo to the same epitopes. These findings indicate that although a restimulatable anti-HTLV-1 CTL activity persists during ATLL, the specific ex vivo response is not constantly maintained. This provides definitive evidence that the CD8+ T-cell response to HTLV-1 is affected by ATLL development and reveals that a major defect concerns the generation and/or the functionality of CD8+ effectors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14574331     DOI: 10.1038/sj.leu.2403176

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

1.  Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Kory R Johnson; Elizabeth M Maloney; Steven Jacobson
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.

Authors:  Hiroya Kobayashi; Toshihiro Ngato; Keisuke Sato; Naoko Aoki; Shoji Kimura; Yuetsu Tanaka; Hitoshi Aizawa; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

3.  The combination of IκB kinase β inhibitor and everolimus modulates expression of interleukin-10 in human T-cell lymphotropic virus type-1-infected T cells.

Authors:  Chie Nishioka; Takayuki Ikezoe; Jing Yang; Keiko Udaka; Akihito Yokoyama
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

4.  Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1.

Authors:  Sharrón L Manuel; Mohit Sehgal; John Connolly; George Makedonas; Zafar K Khan; Jay Gardner; Michael R Betts; Pooja Jain
Journal:  J Clin Immunol       Date:  2013-07-26       Impact factor: 8.317

5.  Long-term persistence of limited HTLV-I Tax-specific cytotoxic T cell clones in a patient with adult T cell leukemia/lymphoma after allogeneic stem cell transplantation.

Authors:  Yukie Tanaka; Hideki Nakasone; Rie Yamazaki; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Masahiro Ashizawa; Tomohito Machishima; Miki Sato; Kiriko Terasako; Shun-ichi Kimura; Misato Kikuchi; Shinya Okuda; Shinichi Kako; Junya Kanda; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal:  J Clin Immunol       Date:  2012-07-05       Impact factor: 8.317

Review 6.  Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.

Authors:  Mari Kannagi
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

7.  Animals Models of Human T Cell Leukemia Virus Type I Leukemogenesis.

Authors:  Stefan Niewiesk
Journal:  ILAR J       Date:  2016

8.  In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine.

Authors:  Divya Sagar; Shet Masih; Todd Schell; Steven Jacobson; Joseph D Comber; Ramila Philip; Brian Wigdahl; Pooja Jain; Zafar K Khan
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

9.  Reduction of human T-cell leukemia virus type 1 (HTLV-1) proviral loads in rats orally infected with HTLV-1 by reimmunization with HTLV-1-infected cells.

Authors:  Kazuya Komori; Atsuhiko Hasegawa; Kiyoshi Kurihara; Takayuki Honda; Hiroo Yokozeki; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

10.  The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases.

Authors:  Mari Kannagi; Atsuhiko Hasegawa; Ayako Takamori; Shuichi Kinpara; Atae Utsunomiya
Journal:  Front Microbiol       Date:  2012-09-03       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.